EU-HTA

From 01 to 29 April 2026 the next JSC request period will open for another three JSC slots, with briefing documents to be submitted between July and September ...

Built together with our European network of local experts, the database delivers all key documents in one place, ...

Most national HTA assessment start once a product is approved. But some begin earlier ...

Pfizer has withdrawn the EU marketing authorisation application for sasanlimab, which in turn means that the associated Joint Clinical Assessment (JCA) has been discontinued ...

Real-World Evidence, RWE, often sounds like a solution to many evidence challenges ...

Ipsen’s tovorafenib for paediatric low-grade glioma received a positive CHMP opinion ...

JCA submission is not the finish line – it’s the start of the most intense phase ...

Usually, EU HTA tasks are handled by Market Access and HOER ...

From challenging local market accesses into a global approval strategy – powered by our network ...